Elsevier

The Lancet

Volume 372, Issue 9645, 4–10 October 2008, Pages 1223-1230
The Lancet

Fast track — Articles
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

https://doi.org/10.1016/S0140-6736(08)61239-8Get rights and content

Summary

Background

Several epidemiological and experimental studies suggest that n-3 polyunsaturated fatty acids (PUFA) can exert favourable effects on atherothrombotic cardiovascular disease, including arrhythmias. We investigated whether n-3 PUFA could improve morbidity and mortality in a large population of patients with symptomatic heart failure of any cause.

Methods

We undertook a randomised, double-blind, placebo-controlled trial in 326 cardiology and 31 internal medicine centres in Italy. We enrolled patients with chronic heart failure of New York Heart Association class II–IV, irrespective of cause and left ventricular ejection fraction, and randomly assigned them to n-3 PUFA 1 g daily (n=3494) or placebo (n=3481) by a concealed, computerised telephone randomisation system. Patients were followed up for a median of 3·9 years (IQR 3·0–4·5). Primary endpoints were time to death, and time to death or admission to hospital for cardiovascular reasons. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00336336.

Findings

We analysed all randomised patients. 955 (27%) patients died from any cause in the n-3 PUFA group and 1014 (29%) in the placebo group (adjusted hazard ratio [HR] 0·91 [95·5% CI 0·833–0·998], p=0·041). 1981 (57%) patients in the n-3 PUFA group and 2053 (59%) in the placebo group died or were admitted to hospital for cardiovascular reasons (adjusted HR 0·92 [99% CI 0·849–0·999], p=0·009). In absolute terms, 56 patients needed to be treated for a median duration of 3·9 years to avoid one death or 44 to avoid one event like death or admission to hospital for cardiovascular reasons. In both groups, gastrointestinal disorders were the most frequent adverse reaction (96 [3%] n-3 PUFA group vs 92 [3%] placebo group).

Interpretation

A simple and safe treatment with n-3 PUFA can provide a small beneficial advantage in terms of mortality and admission to hospital for cardiovascular reasons in patients with heart failure in a context of usual care.

Funding

Società Prodotti Antibiotici (SPA; Italy), Pfizer, Sigma Tau, and AstraZeneca.

Introduction

Despite the impressive therapeutic advances made over the past 15 years, heart failure remains one of the main components of the overall burden of cardiovascular morbidity and mortality.1 Finding innovative ways to prevent cardiovascular death, including sudden cardiac death which accounts for up to half of fatal events, is a major challenge.

The results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione trial2 showed a lower mortality rate in patients taking n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction than in those allocated to the control group. This finding was mainly due to the prevention of sudden death,2, 3, 4, 5, 6 and provided the first clinical controlled confirmation of the possible antiarrhythmic activity of n-3 PUFA. The properties of n-3 PUFA, suggested by observational studies,7, 8, 9, 10 have been extensively documented in cellular and animal models.11 The results of trials in primary and secondary prevention of coronary heart disease have been reviewed and overall suggest that n-3 PUFA is associated with a 20% relative risk reduction of death in high-risk populations, although their efficacy in primary prevention cannot yet be assessed since controlled trials of adequate size in primary prevention have not yet been terminated.7, 10 The potential antiarrhythmic efficacy of n-3 PUFA has been mainly assessed with controversial results in small trials with patients with implanted cardioverter defibrillators.12, 13, 14, 15

No large-scale trial has so far assessed the efficacy of n-3 PUFA in heart failure. Two reasons lent support to the interest of testing n-3 PUFA in a large population of patients with heart failure: first was the large body of experimental evidence for the favourable effects that n-3 PUFA exert on inflammatory processes (including reduction of endothelial activation and cytokine production), platelet aggregation, blood pressure, heart rate, ventricular function, and autonomic tone;16, 17, 18, 19, 20, 21, 22 and second was the safety and tolerability profile of the dose tested in the GISSI-Prevenzione trial,2 which was not expected to cause problems in patients with heart failure who were already pharmacologically treated for their index clinical disorder.

In line with previous GISSI studies,23 a large-scale, randomised, placebo-controlled trial was proposed to a nationwide representative network of hospital and ambulatory-care facilities to test the hypothesis that n-3 PUFA could improve morbidity and mortality of patients with symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF).

Section snippets

Patients

We did a randomised, double-blind, placebo-controlled, multicentre study, involving 326 cardiology and 31 internal medicine centres in Italy (figure 1). The design of the GISSI-HF trial has been described in detail elsewhere, including the randomisation, monitoring, and follow-up procedures.24

Eligible patients were men and women aged 18 years or older, with clinical evidence of heart failure of any cause that was classified according to the European Society of Cardiology (ESC) guidelines as New

Results

7046 patients were randomly assigned (figure 1). We disqualified information from 71 patients at one site after randomisation, before unblinding, because the adequacy of the informed consent process and quality of data could not be ensured. Of the remaining 6975 patients, 3494 were assigned to receive n-3 PUFA and 3481 to placebo. The follow-up was concluded on March 31, 2008. The median duration of follow-up was 3·9 years (IQR 3·0–4·5).

Table 1 shows the baseline characteristics of all

Discussion

Our study shows that the long-term administration of 1 g per day n-3 PUFA was effective in reducing both all-cause mortality and admissions to hospital for cardiovascular reasons. Although this moderate benefit was smaller than was expected, we should note that it was obtained in a population already treated with recommended therapies, was consistent across all the predefined subgroups, and was further supported by the findings of the per-protocol analysis. We noted no adverse effects in the

References (32)

  • Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial

    Lancet

    (1999)
  • R Marchioli et al.

    Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione

    Circulation

    (2002)
  • R Marchioli

    Treatment with polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial

    Eur Heart J

    (2001)
  • A Macchia et al.

    Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids

    Eur J Heart Fail

    (2005)
  • R Marchioli et al.

    Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial

    J Membrane Biol

    (2005)
  • K He et al.

    Fish consumption and incidence of stroke: a meta-analysis of cohort studies

    Stroke

    (2004)
  • Cited by (1163)

    View all citing articles on Scopus

    Members listed at end of paper

    View full text